An official website of the United States government
Home
Name
Aucatzyl
Alternate Names
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
None
Histology
Remarks
November 8, 2024, FDA approved obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). AUTO1 CAR T cells
Coding
This drug should be coded
